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ABSTRACT: The structure−activity relationship was investigated in a
series of synthetic TLR4 antagonists formed by a glucosamine core linked to
two phosphate esters and two linear carbon chains. Molecular modeling
showed that the compounds with 10, 12, and 14 carbons chains are
associated with higher stabilization of the MD-2/TLR4 antagonist
conformation than in the case of the C16 variant. Binding experiments
with human MD-2 showed that the C12 and C14 variants have higher
aﬃnity than C10, while the C16 variant did not interact with the protein.
The molecules, with the exception of the C16 variant, inhibited the LPS-
stimulated TLR4 signal in human and murine cells, and the antagonist
potency mirrored the MD-2 aﬃnity calculated from in vitro binding
experiments. Fourier-transform infrared, nuclear magnetic resonance, and
small angle X-ray scattering measurements suggested that the aggregation
state in aqueous solution depends on fatty acid chain lengths and that this
property can inﬂuence TLR4 activity in this series of compounds.
■ INTRODUCTION
Toll-like receptors (TLRs) are pattern recognition receptors
(PRRs) that recognize pathogen-associated molecular patterns
(PAMPs). TLR4 is mainly expressed on hematopoietic cells
including monocytes, dendritic cells, and macrophages.1
Lipopolysaccharide (LPS), lipooligosaccharide (LOS), and
lipid A from Gram-negative bacteria are generally called
endotoxin and are powerful TLR4 agonists.2 TLR4 responds
rapidly to minute amounts of circulating LPS through a
multistep molecular recognition process, initiated by transfer of
LPS monomers from aggregates in solution to LPS-binding
protein (LBP), and subsequently to cluster to diﬀerentiation 14
(CD14) and to myeloid diﬀerentiation factor 2 (MD-2). MD-2
is associated with TLR4 in MD-2/TLR4 complexes on cell
membrane. In the absence of agonist, the complex TLR4/MD-
2 is in equilibrium between monomeric and dimeric species.
Recent quantitative single-molecule localization microscopy
(SMLM) studies3 have shown that LPS binding to MD-24
displaces the equilibrium toward homodimeric complexes
(TLR4/MD-2/LPS)2.
3,5 The homodimer transmits the signal
downstream through two distinct pathways. One pathway starts
by recruitment of myeloid diﬀerentiation primary response
gene 88 (MyD88) and adapter myelin and lymphocyte protein
(MAL) (MyD88-dependent pathways and production of a
number of pro-inﬂammatory proteins), the other by the
activation of TIR-domain-containing adapter-inducing interfer-
on-γ (TRIF) (MyD88-independent pathways and production
of interferons).6
In addition to bacterial PAMPs, TLR4 can be also activated
by damage-associated molecular patterns (DAMPs), endoge-
nous agonists responsible for sterile inﬂammation, such as
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ﬁbronectins,7 saturated palmitic acid,8 oxidized phospholipids,9
or high-mobility group box 1 (HMGB1) protein10 which have
also been shown to activate TLR4. While diﬀerent LPS
chemotypes share a conserved lipid A moiety with chemical
determinants that ensure optimal interaction with CD14 and
MD-2 (ﬁve or six lipophilic fatty acid chains attached to a
disaccharide backbone, and one or two phosphate groups),
DAMPs are chemically diverse molecules, and the molecular
mechanism of TLR4 activation including the role of CD14 and
MD-2 in the sensing of these molecules are not entirely
understood. DAMPs have been implicated in many pathologies
caused by TLR4 activation including atherosclerosis,11
rheumatoid arthritis,12 neuroinﬂammation,13 trauma,14 and
hemorrhage.15
These ﬁndings strongly support the idea that regulation of
TLR4 activity appears as a potential target for therapeutic
control of a variety of inﬂammatory-based diseases. Manipu-
lation of TLR4-mediated immune responses as a potential
approach for pharmacological intervention has been reported in
the literature.16 For the past few years, several TLR4
antagonists have been evaluated in preclinical studies, but
only two drugs, E556417 (Eritoran, Eisai, Inc.) and TAK-24218
(Takeda Biological), progressed to clinical trials for treatment
of sepsis, which have been discontinued in diﬀerent phases.19,20
Eﬃcient and selective TLR4 antagonists with a chemical
structure simpler than lipid A are the basis for development of
novel TLR4 modulators. Lipid A consists of a 1,4-
diphosphorylated diglucosamine backbone to which variable
lengths and numbers of fatty acid (FA) acyl chains are
covalently linked.2 Lipid X (Figure 1),21 a biosynthetic
precursor of lipid A with TLR4 antagonist activity, has been
considered a simpliﬁed monosaccharide scaﬀold for the
development of novel TLR4 modulators.
Our group developed the lipid X mimetic FP7,6 a
glucosamine derivative with two phosphate groups and two
myristic (C14) fatty acid (FA) chains, whose design was
inspired by other glucosamine-based TLR4 modulators.22−24
FP7 is active in inhibiting in a dose-dependent way human6 and
murine25 TLR4 activation by LPS. Some preliminary
observations from nuclear magnetic resonance (NMR) experi-
ments suggest that FP7 interact with MD-2, probably inserting
FA chains into hydrophobic binding cavity.6 This direct
competition with LPS for MD-2 binding is probably reinforced
by the capacity of FP7 to induce endocytosis of CD14, thus
causing the absence of this receptor on the plasma membrane.6
FP7 is active in blocking PR8 virus lethality that is mainly due
to TLR4 overstimulation by endogenous DAMPs (mainly
oxidized phospholipids and HMGB-1 protein) derived from
viral damage to lung tissue.25 In a proof-of-concept experiment
in support of this in vivo mechanism, FP7 inhibited HMGB-1
activation of dendritic cells.25 Other monosaccharide-based
TLR4 modulators were developed, and structure−activity
relationship (SAR) studies showed that the length of FA
chain is a critical factor determining the potency of TLR4
antagonism or agonism.22,26 The biological activity and the
agonist/antagonist behavior on TLR4 of lipid A variants and
other amphiphilic glycolipids including FP7 is not only
determined by the interaction with MD-2 but also by the
aggregation state in solution. Like LPS and lipid A, FP7 is an
anionic amphiphile with a low value of CMC (9 μM).6 Even
though the CMC value of FP7 is higher than its IC50 (about 2
μM in HEK cells assays), equilibrium between aggregates and
single molecules in solution is present in the concentration
range in which FP7 is active.
It has been proposed for lipid A derivatives that the size and
the 3D shape of aggregates inﬂuence the TLR4 activity, lamellar
aggregates being associated with antagonism, and aggregates
with nonlamellar cubic symmetry to agonism.27,28 While the
last step of ligand presentation to TLR4 and formation of the
activated heterodimer (TLR4/MD-2/ligand)2 is dominated by
single molecule interactions between the ligand and CD14 and
MD-2 receptors,29 the early phases of endotoxin (ligand)
recognition by LBP are very likely inﬂuenced by the
aggregation state of the ligand.
We present here a SAR study on synthetic FP7 variants
diﬀering only for FA chains lengths (10, 12, 14, and 16 carbon
atoms, Figure 1). In this study we will take into account both
the interaction with MD-2 and the aggregation properties of
the molecules. Additionally, we show the relationship between
the chemical structure of FP7 variants with diﬀerent fatty acid
chains lengths and their eﬀect on functional activity of TLR4 in
diﬀerent in vitro cell models.
■ RESULTS
Computational Design of FP7 Variants as Ligands of
Human MD-2 and CD14. Given our previous studies on the
lipid X mimetic FP7 as ligand of TLR4/MD-2 and CD14
proteins, with TLR4/MD-2 antagonist activity,6 we were
prompted to investigate the inﬂuence of the acyl chain length
on the antagonist activity. To address this point, we designed
three new FP7 derivatives with diﬀerent fatty acid (FA) lengths:
FP10 (C10), FP12 (C12), FP7 (C14), and FP116 (C16). The
ability of these ligands to bind to TLR4/MD-2 complex and to
CD14, compared with FP7, was initially assessed through
various computational techniques.
We ﬁrst docked the ligands in the binding site of CD14 using
AutoDock Vina. For all the four ligands, docked poses inside
the hydrophobic pocket were found. The obtained binding
poses were very similar for all the ligands (Figure S1A) with
also very close favorable predicted binding energies for the top
poses (range from −6.5 to −5.9 kcal mol−1). Therefore, the
docking calculation showed that all four ligands are
theoretically able to interact with CD14 inside its hydrophobic
pocket and to engage in favorable interactions. In the most
populated and most favorable docked poses, one phosphate
group is interacting with the NH groups of Arg72 and Val73
and with the OH group of Tyr82 (Figure S1B), while the other
Figure 1. Chemical structures of lipid X and FP7 variants.
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phosphate group is exposed to the solvent. The FA chains are
accommodated inside the hydrophobic pocket of CD14
interacting with aliphatic residues, mainly Ala, Val, Leu, and
Ile residues and aromatic Phe49 (details are depicted in Figure
S1C). The results were in agreement with previous docking
studies of FP7 reported by us.30
We performed the docking calculations of ligands FP7, FP10,
FP12, and FP116 inside the TLR4/MD-2 complex in the
antagonist conformation (Figure 2). For all the compounds,
favorable docked poses were found, with predicted binding
energies, for the best ones, ranging from −7.8 to −6.5 kcal
mol−1. The polar head groups are placed at the rim of MD-2
and the FA chains go deep inside the hydrophobic pocket
interacting with many hydrophobic residues, namely, Val24,
Ala30, Ile32, Ile44, Ile46, Val48, Ile52, Leu54, Leu61, Ile63,
Tyr65, Phe76, Leu78, Ile80, Phe104, Val113, Ile117, Phe119,
Phe121, Ile124, Tyr131, Val135, Phe147, Leu149, Phe151, and
Ile153 (Figure 2B).
Additionally, it was possible to observe more diversity in the
predicted binding poses in TLR4/MD-2 than in the case of
CD14. Results for FP7 were in agreement with those previously
reported in MD-2 protein.6 In many poses, one of the
phosphate groups was close to the hydroxyl group of MD-2
Tyr102 where it establishes hydrogen bonds, and the other one
was often close to MD-2 Arg90 establishing hydrogen bonds
and electrostatic interactions (Figure 2C). In some docked
poses, the phosphate groups were observed to interact with the
backbone of residues Phe119, Ser120, and Phe121. Both
phosphate groups were often placed at the rim of MD-2 where
they are exposed to the solvent, in agreement with the reported
X-ray crystallographic complexes of TLR4/MD-2 with
glycolipids (for example, complex with Eritoran, PDB-ID
2Z65, or with lipid IVa, PDB-ID 2E59). Two diﬀerent
orientations were also found: type A (antagonist-like binding
mode), similar to that found for lipid IVa in PDB-ID 2E59; and
type B (agonist-like binding mode), similar to that found for E.
coli lipid A in PDB-ID 3FXI (Figure S2). It is well-known that
these two ligands, lipid IVa and E. coli lipid A, bind to TLR4/
MD-2 in a diﬀerent manner, one being rotated 180° compared
to the other one, leading to opposed biological activities.
Selected binding poses were used as starting structures for
redocking with AutoDock4 resulting in predicted binding
energies ranging from −4.6 to +4.3 kcal mol−1. Among the
docked solutions, the best poses (from −4.6 to −2.5 kcal
mol−1) corresponded to binding poses very similar to those
obtained with AutoDock Vina (data not shown). The narrow
binding energy range did not permit to rank the ligands by
predicted aﬃnity, showing that the four ligands are putative
binders of the TLR4/MD-2 system. Given that the main
interactions (the polar ones) are common to the four ligands
and that the MD-2 pocket is big enough to host two longer FA
chains, from the docking calculations, it was not possible to
clearly correlate the subtle diﬀerences in FA chain length with
preferred ligand binding.
Stability of the predicted TLR4/MD-2/ligand complexes was
further studied by molecular dynamics (MD) simulations. We
selected two of the best binding poses for each ligand (Figure
S3): one type A (antagonist-like binding pose) and one type B
(agonist-like binding pose), plus two additional poses for
compounds FP10 and FP7. Therefore, a total of eight 50 ns
MD simulations were run. We monitored the motion of MD-2
over time and examined the root-mean-square deviation (rmsd)
and rms ﬂuctuation per residues, as well as the motion of
Phe126 side chain over time (Figure S4). All the complexes
showed stable ligand−receptor interactions along the MD
simulation time as predicted by the docking calculations. In
particular, in the MD simulation of the TLR4/MD-2/FP7
complex in the type A (antagonist-like) binding pose, the
Phe126 side chain moves around its initial position staying
largely exposed to the solvent in a conformation in agreement
with the X-ray crystallographic antagonist conformation of MD-
2 (Figure 3A).
Figure 2. (A) General view of FP10 (in orange), FP12 (in yellow), FP7 (in green), and FP116 (in violet) ligands are shown docked inside TLR4/
MD-2 (TLR4 is shown in black and MD-2 in gray). (B) Detail of the MD-2 hydrophobic pocket occupied by all the best docked poses for each
ligand (represented as lines). Hydrophobic residues mentioned in the text as interacting with the FA chains of the ligands are represented in spheres.
(C) Detail of the polar interactions of the ligands inside the TLR4/MD-2 system. Phosphate groups of the best docked poses of each ligand and the
MD-2 residues with which they interact are represented in sticks.
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To evaluate the relative orientation between the ligands and
MD-2, we arbitrarily deﬁned two vectors, one from the amide
carbon atom to the ester and carbon atom of the ligand, and
another one from the carbon of residues Pro78 to Thr105 of
MD-2 (Figure S5A). The angle between these two vectors was
plotted both over time and as a percentage of frames per 0.1
degree angle range (Figure S6). It was observed that none of
the ligands undergoes orientation ﬂip during the 50 ns
simulations; all remain in the orientation from the docking
process. Interestingly, only in the case of the TLR4/MD-2/
FP116 complex with FP116 in the type A (antagonist-like)
binding pose does the orientation of Phe126 side chain ﬂip over
(Figure 3B). We monitored this ﬂipping behavior along the
MD simulations, for all the ligands, by arbitrarily choosing two
vectors, within MD-2, both starting from the carbon of residue
Phe126 to, respectively, the phenyl C-4 atom of the same
residue and the carbon of residue Ser21 (data shown in Figures
S5B and S7). This observation could suggest that FP116 is not
able to eﬃciently retain an antagonist conformation of MD-2,
thus pointing to a poor antagonist capacity.
Additionally, logP values of compounds FP10, FP12, FP7,
and FP116 were computationally calculated, ranging from
approximately 4 to 10 with a linear distribution (Figure S8).
The highest logP value was obtained for FP116 indicating a
high lipophilicity that might result in low water solubility. This
was in agreement with the lower acyl chain mobility as analyzed
by Fourier-transform infrared (FT-IR) spectroscopy (see
below). In any case, this did not interfere with the performance
of the cell assays. Summarizing, the computational studies
assessed the ability of ligands FP7, FP10, FP12, and FP116 to
bind both CD14 and TLR4/MD-2, pointing to the long FP116
acyl chain (C16) as the maximum length bordering good
Figure 3. Superimposition of diﬀerent snapshots (one for each
simulated nanosecond), from the MD simulations of the TLR4/MD-
2/ligand complexes, colored from blue (t = 0 ns) to red (t = 50 ns).
Only ligands (as lines) and Phe126 (in sticks) are made visible. Side
chains of Phe126 from the X-ray crystallographic structures have been
superimposed to the snapshots to illustrate the antagonist (dark blue,
PDB-ID 2E59) and agonist (black, PDB-ID 3FXI) conformations of
MD-2. (A) TLR4/MD-2/FP7 complex starting from the type A
binding pose (antagonist-like). (B) TLR4/MD-2/FP116 complex
starting from the type A binding pose (antagonist-like).
Scheme 1a
aReagents and conditions: (a) CuSO4, TEA, Py:H2O, 0 °C, 30 min then TfN3, Py, 0 °C−rt, O.N., quant.; (b) p-MeOPhCH(OMe)2, CSA, DMF dry,
40 °C, 8 h, 68%; (c) TBSCl, imidazole, CH2Cl2 dry, rt, 1.5 h, 62%; (d) PPh3, THF/H2O, 60 °C, 2 h, quant.; (e) decanoic acid, EDC, DMAP,
CH2Cl2 dry, rt, 6 h, 79%; (f) lauroyl chloride, DMAP, Py dry, 0 °C−rt, O.N., 79%; (g) palmitoyl chloride, DMAP, Py dry, rt, O.N., 75%; (h)
NaCNBH3, 4 Å MS, THF dry, rt, O.N., then HCl 1 M in dioxane until pH 2, 12−70%; (i) (BnO)2PNiPr2, imidazolium triﬂate, CH2Cl2 dry, rt, 30
min, then m-CPBA, 0 °C−rt, O.N., 51−56%; (j) (i) H2, Pd/C, MeOH dry/CH2Cl2 dry, rt, O.N., (ii) Et3N, (iii) IRA 120 H+ resin, (iv) IR 120 Na+,
84%-quant.
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(predicted) binding properties. The compounds were therefore
synthesized and tested.
Synthesis of FP Variants. Compounds FP7, FP10, FP12,
and FP116 were synthesized according to a divergent synthetic
strategy starting from the common precursor 4 (Scheme 1).
Commercially available D-glucosamine hydrochloride was
converted into the intermediate 4 by subsequent protection of
C-4 and C-6 positions as p-methoybenzylidene and the
anomeric (C-1) position as tert-butyldimethylsislyl (TBDMS)
ether.6 Intermediate 4 was then acylated in positions C2 and
C3 according to three diﬀerent procedures, obtaining
monosaccharides 8, 9, and 10 with, respectively, C10, C12,
and C16 carbon FA chains. Compound FP7, with C14 chains,
was obtained similarly following a published procedure.6
Regioselective p-methoxybenzylidene ring opening as p-
methoxybenzyl (PMB) ether in C-6, followed by phosphor-
ylation of free hydroxyls in positions C1 and C4, and ﬁnal
deprotection of PMB ethers gave ﬁnal compounds as
triethylammonium ions. Exchange of triethylammonium with
sodium (IR120 Na+ ion-exchange resin) followed by reverse-
phase puriﬁcation gave ﬁnal compounds FP10, FP12, and
FP116 with a purity ≥95%.
Aggregation Properties of FP Compounds. FT-IR
Studies. The mobility of the acyl chains is an important
biophysical parameter of aggregated lipids. Biological lipids
typically show a temperature-dependent phase transition from a
highly ordered gel (Lβ) phase of the hydrocarbon chains at low
temperatures (indicated by an absorption peak around 2850
cm−1) to a liquid-cystalline (Lα) phase at higher temperatures
(indicated by a absorption peak around 2852 cm−1). The phase
transition temperature (Tc) is characteristic of the chemical
structure of the lipids. The FP compounds were analyzed by
FT-IR spectroscopy to determine the lipid phase in depend-
ence of temperature. FP compounds with shorter acyl chains
(FP10, C10 and FP12, C12) were found to be in a ﬂuid Lα
phase with high mobility of their acyl chains at all temperatures.
FP compounds with longer acyl chains (FP7, C14 and FP116,
C16) showed a biphasic behavior with a clear Lβ to Lα phase
transition with Tc around 28.5 °C for FP7 and around 40.2 °C
for FP116 (Figure 4). Notably, the main phase transition of
FP116 at 40.2 °C occurs along a broad temperature range, and
a second phase transition is observed around 65 °C. Thus, at a
biological relevant temperature of 37 °C, FP10, FP12, and FP7
exhibit a ﬂuid membrane phase, whereas FP116 is still in a rigid
membrane phase and requires much higher temperatures for
acyl chain melting to occur.
NMR Studies. The comparison of the 1H NMR spectra
recorded after compound dissolution in phosphate buﬀer, pH
7.4, 25 °C (Figure S9) suggested a diﬀerent aggregation state of
the bioactive compounds in solution in the micromolar
concentration range. The 1H NMR spectrum acquired on a
100 μM FP7 sample (Figure S9A) clearly showed the presence
of two sets of signals, as can be deduced by observing the
spectral region between 5.5 and 5.2 ppm. In addition to a
doublet of doublet and a triplet, corresponding to H1 and H3
protons (*), also two broad resonances (§) are present that can
be assigned to aggregated species. This hypothesis was
supported by the comparison of spectrum S9A with FP7
spectra recorded at higher concentrations, in particular 125 μM
(Figure S9B) and 250 μM (Figure S9C), where the gradual
decrease in sharp signal (*) intensity is associated with the
increase of the broad resonance (§) ones, as expected as a
consequence of FP7 aggregation. A further conﬁrmation was
achieved through the acquisition of relaxation-edited (Figure
S9D) and diﬀusion-edited (Figure S9E) spectra, employed to
partially ﬁlter out resonances from high molecular weight and
low molecular weight species, respectively.31,32 Indeed, the
spectrum acquired with the CPMG sequence (Figure S9D),
edited on the basis of relaxation times and thus highlighting the
signals from low molecular weight species, showed a decrease
of broad signal (§) intensities compared to spectrum S9C; on
the contrary, in the diﬀusion-edited spectrum (Figure S9E),
whose parameters were set up to erase resonances from low
molecular weight compounds, sharp resonances (*) disap-
peared. We can conclude that, under our experimental
condition, FP7 was present in solution as a mixture of
monomer/small aggregates and higher aggregated species
(micelles), whose equilibrium changes coherently to the
variation of the nominal concentration of the molecule.
Instead, only one set of sharp signals was observed in the 1H
NMR spectra recorded on FP10 and FP12 solutions containing
the compounds in the concentration range 100 μM to 1 mM.
Representative spectra acquired on 500 μM samples are
depicted in Figure S9F−H for FP10 and Figure S9I−M for
FP12. Furthermore, FP10 and FP12 resonances appear
considerably narrower compared to FP7 signals (Figure S9A).
Collectively, these ﬁndings suggest an appreciably higher
solubility of FP10 and FP12 in aqueous buﬀer solution and
thus a lower propensity to form micelles.
A diﬀerent behavior can be described for FP116. All the 1H
NMR spectra acquired on this compound present broad
resonances and no sharp signals, expected for the free
monomer. Thus, in the range of tested concentrations (125−
500 μM), FP116 is always present in an aggregated form.
Representative spectra acquired on a 250 μM FP116 sample are
reported in Figure S9N−P.
SAXS Studies. Small angle X-ray scattering (SAXS) proﬁles
were measured in dependence of temperature to obtain
information on the supramolecular organization of the
molecules. The data are given in the range of the scattering
vectors relevant for structure assignment. All FP compounds
showed isotropic scattering, indicating no preference for a
predominant orientation of the aggregates. FP10 and FP12
showed diﬀuse symmetric scattering curves dominated by the
Figure 4. Acyl chain mobility of the aggregated FP compounds in
dependence on temperature. The infrared absorption around wave-
numbers 2850−2852 cm−1 corresponds to the symmetric stretching
vibrations νs of the CH2 groups of the acyl chains. The wavenumbers
indicated were derived from the peak absorption of νs(CH2)
determined upon constant heating of the samples. Data are
representative of two independent measurements.
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form factor, which is characteristic for unilamellar aggregates
with large interbilayer distance and probably owing to the
negative surface charge of the two adjacent phosphate groups
that leads to a net electrostatic repulsion of the bilayers (Figure
5). The scattering of FP10 shows two maxima at 5.58 nm and
at 3.38 nm, the latter could indicate the formation of
interdigitated bilayers (3.38 nm). For FP12, a single peak is
observed at 20 °C (up to 35 °C, data not shown) indicating the
formation of correlated multilayers with a d-spacing of 4.14 nm,
which is also consistent with the formation of an interdigitated
bilayer structure. In contrast, FP7 does show a diﬀerent and
more complex scattering pattern, which indicates the
occurrence of a nonlamellar structure. The spacing relationship
exhibits clear similarity with cubic structures with a space group
relationship of aQ 12.7 nm (not visible), aQ/√3 (7.29 nm),
aQ/√5 (5.68 nm), aQ/√8 (4.53 nm), and aQ/√11 (3.86
nm), agreeing most likely with space group Q212. The tendency
to a nonlamellar structure of FP7, however, could explain the
slightly lower antagonistic activity of FP7 compared to FP12. In
contrast to the above FP compounds, FP116 showed very weak
scattering intensities, hardly displaying a form factor, which can
be explained by a much lower solubility observed for the FP116
preparation and supports the results obtained by NMR.
Binding to MD-2. Expression, Puriﬁcation, and Activity of
hMD-2. Recombinant human MD-2 (hMD-2) was used in in
vitro binding experiments. The functionality of this protein is a
crucial prerequisite to obtain reliable results representative of
speciﬁc, high-aﬃnity molecular recognition of ligands.33
Recombinant hMD-2 was expressed in E. coli, Pichia pastoris,
and mammalian HEK293 cells. hMD-2 from diﬀerent hosts was
tested for its activity by incubating HEK/hTLR4 cells with a
mixture of recombinant hMD-2 and LPS (100 ng/mL). The
TLR4-dependent IL-8 secretion by HEK/hTLR4 cells is
indicative of functional MD-2. Figure 6 shows the lowest
concentration of MD-2 required for maximum activation of
TLR4 (quantiﬁed by IL-8 production), for each of the diﬀerent
expressed and puriﬁed hMD-2 proteins. hMD-2 produced and
puriﬁed from HEK293T displayed the highest activity in
stimulating the LPS/TLR4 inducible reporter at a concen-
tration of 12 nM, followed by the hMD-2 expressed and
puriﬁed from P. pastoris with its highest biological activity
obtained at a concentration of 15 nM. Finally, hMD-2 puriﬁed
from E. coli gave the lowest IL-8 production at the
concentration of 245 nM (Figure 6).
The diﬀerence in activity of hMD-2 expressed in diﬀerent
hosts most likely reﬂects minor diﬀerences in protein folding
and/or glycosylation.34,35 The higher expression yield and the
good activity prompted us to use hMD-2 from P. pastoris in in
vitro binding experiments with synthetic compounds.
Binding studies were carried out by means of fours diﬀerent
techniques: two ELISA-type plate-based assays with immobi-
lized protein, a ﬂuorescence displacement assay, and surface
plasmon resonance (SPR).
ELISA Competition Experiments with Anti-hMD-2 Anti-
body. Direct binding of LPS, FP7, FP10, and FP12 to MD-2
was determined using a monoclonal antibody that binds to free
hMD-2 but not to hMD-2 bound to LPS.36 Monoclonal mouse
anti-hMD-2 (9B4) antibody speciﬁcally binds to an epitope
close to the rim of the LPS-binding pocket of hMD-2, available
for recognition by the antibody only when the hMD-2 pocket is
empty.
Figure 5. Small angle X-ray diﬀraction of aggregates in solution for FP10 (A), FP12 (B), FP7 (C), and FP116 (D). Scattering vectors are indicated
for temperatures between 20 and 80 °C. Gray squares show enlargements of the relevant scattering vectors. The spacing of the diﬀraction maxima is
indicted as d = 1/s (nm).
Figure 6. Activity of hMD-2 expressed in diﬀerent hosts. The ﬁgure
shows the maximum activation of TLR4 (quantiﬁed by IL-8
production) at the lowest concentration of hMD-2 under the diﬀerent
expressed conditions (bacteria 245 nM, yeast 15 nM, and mammalian
12 nM). Results are mean ± SEM from three parallels representative
of at least three independent experiments.
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This assay detected a decrease in binding to MD-2 in the
presence of LPS (Figure 7A), similar to that previously
reported.37 A dose-dependent inhibition of antibody/MD-2
interaction was observed when adding FP7 and FP12, with a
90−95% decrease in binding obtained at concentrations of FP7
and FP12 of 20 μM (Figure 7A). A 70% decrease in binding to
hMD-2 was obtained with 20 μM of FP10 (Figure 7A), and a
20% decrease was obtained with 20 μM of FP116 (Figure 7A).
These data showed that, while FP7 and FP12 bind hMD-2 with
high aﬃnity, FP10 and FP116 are less potent ligands.
ELISA Displacement Experiment with Immobilized hMD-2
and Biotinylated LPS. The ability of FP compounds to displace
LPS from the pocket of hMD-2 was assessed by an ELISA
plate-based assay. The synthetic molecules were added at
increasing concentration to hMD-2, which was already
incubated with biotinylated LPS. FP7 and FP12 were able to
displace biotin-LPS from hMD-2 in a dose-dependent manner,
with the highest displacement of 60−65% obtained at a
concentration of 160 μM (Figure 7B). FP10 and FP116, at a
concentration of 160 μM, gave a displacement of biotin-LPS of
20−30% (Figure 7B). As a control, LPS at a concentration of
40 μM gave the highest displacement of biotin-LPS of 70%
(Figure 7B).
Fluorescence Displacement Assay. It has been previously
shown that the ﬂuorescent probe 1,1′-Bis(anilino)-4,4′-bis
(naphthalene)-8,8′ disulfonate (bis-ANS) binds to MD-2 and is
displaced by LPS.38 bis-ANS presumably binds the same MD-2
binding site as lipid A and of other lipid A-like ligands. TLR4
ligands interacting with MD-2 in a lipid A-like manner are
supposed to compete with bis-ANS and displace it from MD-2.
LPS, FP7, FP10, and FP12 caused a concentration-dependent
decrease of bis-ANS ﬂuorescence, indicating competitive
binding of FP7, FP10, and FP12 to hMD-2 (Figure 7C).
FP116 induces only a modest decrease of bis-ANS ﬂuorescence
Figure 7. Cell-free binding studies on puriﬁed\ hMD-2 receptor. (A) LPS, FP7, FP10, and FP12 prevent anti-human MD-2 monoclonal antibody
binding in a dose-dependent manner. (B) LPS, FP7, FP10, FP12, and FP116 activity in competing with biotin-LPS for hMD-2 binding. (C)
Fluorescence measurements show that LPS, FP7, FP10, and FP12 dose-dependently inhibit the binding of bis-ANS to MD-2. (D−H) SPR analysis
shows direct interaction between LPS, FP10, FP12, FP7, and FP116 and MD-2; KD values are reported. Results are mean ± SEM from three parallels
representative of at least three independent experiments.
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at the tested concentrations (Figure 7C), thus conﬁrming that
the lack of activity on cells could be related to low aﬃnity
binding of this molecule to hMD-2.
Surface Plasmon Resonance (SPR) Analysis. SPR data with
immobilized hMD-2 showed direct interaction of the receptor
with LPS (control) and with the tested synthetic compounds.
KD values derived from sensorgram analysis were 3, 13.7 , 22,
and 66.8 μM for FP12, FP7, FP10, and FP116, respectively
(Figure 7E−H). SPR experimental curve optimal ﬁtting was
obtained by assuming 1:1 ligand/MD-2 binding stoichiometry.
Together, the results obtained from these in vitro cell-free
studies clearly indicate that FP7, FP10, FP12, and FP116
Figure 8. Dose-dependent inhibition of LPS-triggered TLR4-dependent NF-kB activation in HEK-Blue hTLR4 cells by compounds FP7, FP10,
FP12, and FP116. (A) HEK-Blue hTLR4 cells were preincubated with the indicated concentrations of compounds FP7, FP10, FP12, and FP116 and
stimulated with LPS (100 ng/mL) after 30 min. Data were normalized to stimulation with LPS alone and expressed as the mean percentage ± SEM
of at least three independent experiments. (B) Dose−response curves for compounds FP7, FP10, and FP12 in inducing the TLR4-dependent NF-κB
reporter activity. Concentration−eﬀect data were ﬁtted to a sigmoidal four-parameter logistic equation to determine IC50 values. Data points
represent the mean of percentage ± SEM of at least three independent experiments.
Figure 9. Activity of compounds FP10, FP12, and FP116 on RAW-Blue cells. (A) RAW-Blue cells were preincubated with increasing concentrations
of synthetic compounds and then stimulated with LPS (10 ng/mL, after 30 min). Data were normalized to the response to LPS and expressed as the
mean percentage ± SEM of at least three independent experiments. (B) Dose-dependent inhibition curves of compounds FP7, FP10, and FP12. IC50
values in the table on the bottom. Concentration−eﬀect data were ﬁtted to a sigmoidal four-parameter logistic equation to determine IC50 values.
Data points represent the mean of percentage ± SEM of at least three independent experiments.
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directly interacted with MD-2, with the same order of potency
found in human and murine cell experiments FP12(C12) >
FP7(C14) > FP10(C10) ≫ FP116(C16).
Cell Experiments. Modulation of LPS-Stimulated TLR4
Signaling in HEK-Blue Cells. In order to evaluate the inﬂuence
of the fatty acid length on the TLR4 antagonist activity,
molecules FP10, FP12, FP7, and FP116, constituting the
homologous series with fatty acid chain lengths C10, C12, C14,
and C16, were ﬁrst tested on HEK-Blue hTLR4 cells. These
cells are engineered to stably express the human receptors of
the LPS recognition complex (hTLR4, hMD-2, and hCD14)
and a reporter gene (SEAP) placed under the control of two
TLR4-dependent transcription factors (NF-κB and AP-1).
Results from MTT assay revealed that all compounds did not
have a negative eﬀect on cell viability at the concentration of 10
μM used in experiments (Figure S10). FP7, FP10, and FP12,
but not FP116, inhibited in a concentration-dependent manner
the TLR4 signaling in HEK-Blue cells (Figure 8). FP7
displayed the expected antagonistic activity.6 FP10 and FP12
showed IC50 respectively higher (5.45 μM) and lower (0.63
μM) than FP7 (2.0 μM) (Figure 8B). These results
demonstrated the eﬃcacy of fatty acid chains lengths (C8,
C10, and C12) of FP7 variants to negatively modulate TLR4
signaling in HEK-Blue cells, the order of activity being
FP12(C12) > FP7(C14) > FP10(C10) ≫ FP116(C16).
Modulation of LPS-Stimulated TLR4 Signaling in Murine
Macrophages. Several TLR4 modulators mimicking lipid A
have diﬀerent eﬀects on human and murine TLR4. In certain
cases when passing from murine to human TLR4/MD-2/CD14
system the observed agonistic eﬀect switched to antagonistic
eﬀect of the compound of interest.39 The species speciﬁcity is
due to diﬀerences between hMD-2 and mMD-2 binding
regions that induce diﬀerent positioning of the same ligand,
thus causing diﬀerent activity and, in some cases, switch from
agonism to antagonism. In this experiment, we aimed to
investigate the eﬀect of glucosamine derivatives in murine
RAW-Blue macrophages. These cells are derived from RAW
264.7 and possess the same reporter gene present in HEK-Blue
hTLR4 cells (SEAP). We ﬁrst veriﬁed the capacity of FP
compounds to stimulate the TLR4 response in RAW-Blue cells,
and we found all molecules inactive (Figure S11). When
administrated before LPS, FP7, FP10, and FP12 were active in
inhibiting TLR4-dependent NF-κB activation in RAW-Blue
macrophages (Figure 9A,B). Similarly to what happened in the
case of human HEK cells, FP116 turned out to be inactive as
antagonist. Notably, FP12 was the most active antagonist
compound (IC50 = 1.7 μM). The activity order of the tested
compounds was found to be the same than in human HEK
cells: FP12(C12) > FP7(C14) > FP10(C10) ≫ FP116(C16).
Eﬀect of FP Variants on LPS-Induced TLR4 Signaling
in THP-1 Cells. Haematopoietic TLR4 has been shown to play
a critical role in any stage of the inﬂammatory process.
Furthermore, immune competent cells use TLR4 signaling to
sense danger molecules and produce proinﬂammatory proteins
that initiate and amplify the inﬂammatory process. To test the
potential of FP variants to modulate TLR4 signaling pathways,
we utilized THP-1 cells as an in vitro model. Initially, we
evaluated the eﬀect of FP variants on THP-1 cell viability.
THP-1 cells were exposed to diﬀerent concentrations of FP
variants (0−10 μM) in the presence or absence of LPS (100
ng/mL) for up to 24 h. Results from MTT assay demonstrated
that FP variants/LPS did not aﬀect cell viability (Figure S12).
Figure 10. Eﬀect of FP variants on LPS/TLR4 induced production of IL-8 in THP-1 cells. THP-1 cells were pretreated with FP variants (0−10 μM)
for 1 h prior to LPS exposure. Cells were then left to incubate 16 h further in the presence or absence of LPS (100 ng/mL). IL-8 production was
measured by ELISA. Results are displayed as mean concentration ± SD of three independent experiments. Signiﬁcant results are indicated as *P >
0.05, **P > 0.01, ***P > 0.001 for LPS vs control and LPS vs FPs treated samples (ANOVA).
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To determine the eﬀect of FP variants on TLR4 signaling, next
we analyzed IL-8 expression, a well-known TLR4-dependent
proinﬂammatory cytokine produced in THP-1 cells in response
to LPS. ELISA results clearly demonstrated the potential of FP7
and FP12 at 10 μM to inhibit LPS driven IL-8 production
(Figure 10). In contrast, FP10 and FP116 had a modest or
nonsigniﬁcant impact on IL-8 expression, respectively (Figure
10). We have demonstrated that FP7 exerted a negative eﬀect
on TLR4 signaling in diﬀerent cell types (unpublished data).
Following on from comparative analysis based on TLR4-
dependent IL-8 expression and tendency on the binding aﬃnity
with MD-2 of FP7 variants, we found that the structural
modiﬁcation of FP12, but not FP10 and FP116, is related to
antagonistic activity of the compound. In support to this
notion, we further investigated the ability of FP12 to modulate
second messengers in TLR4 signaling. Immunoblotting data
revealed that FP12 signiﬁcantly downregulated p65 NF-κB
phosphorylation that was associated with a strong inhibition of
the expression of additional TLR4-dependent cytokines, such as
IL-6 and IL-1β in a dose-dependent manner (Figure 11). These
data clearly demonstrate that FP12 is a potent negative
regulator of TLR4 signaling in THP-1 cells.
■ DISCUSSION AND CONCLUSIONS
The homologous series of FP glycolipids with fatty acid chain
lengths varying from 10 to 16 carbon atoms was rationally
designed as MD-2 ligands and synthesized.
In a ﬁrst set of in vitro experiments, we aimed at studying the
SAR of these molecules in binding experiments with functional
hMD-2. For this purpose, hMD-2 expressed in yeast (P.
pastoris) was used because it showed higher activity in
responding to LPS stimulus than bacterial (E. coli) MD-2 and
was produced with higher yields than MD-2 from mammalian
(HEK) cells. Four diﬀerent binding experiments between
synthetic compounds and h-MD-2 were carried out. These
were competition (displacement) experiments in which the
synthetic glycolipids compete with biotin-LPS, with the
ﬂuorescent MD-2 ligand bis-ANS, and with anti-MD-2
antibody for MD-2 binding. SPR measurements allowed to
analyze directly the binding between synthetic glycolipids and
MD-2. All binding experiments consistently provided the same
order of aﬃnity among hMD-2 and synthetic molecules:
FP12(C12) > FP7(C14) > FP10(C10) > FP116(C16).
The biological activity was then assessed on cells: when
provided alone, the synthetic FP compounds did not display
any TLR4 agonist activity in human and murine cells. On the
contrary, when administrated with LPS, the molecules with 10,
12, and 14 carbon chains (respectively, FP10, FP12, and FP7)
were active in blocking LPS/TLR4 signal (antagonism) in
human and murine cells, while the molecule with 16 carbons
(FP116) showed very weak or no activity. The order of activity
of FP variants as TLR4 antagonists was conﬁrmed in human
(HEK-TLR4 and THP-1) and murine (RAW macrophages)
cells. The molecules with 10, 12, and 14 carbon chains seem to
be nonspecies-speciﬁc TLR4 antagonists because these
compounds are active in both human (HEK and THP-1) and
murine cells, with higher potency in human ones. The
compound with higher biological activity was FP12, with 12
carbons, followed by FP7 and FP10 with 14 and 10 carbons,
while FP116 with 16 carbons showed very weak or no activity
in cell models.
The variation of compounds’ functional activity was related
to the number of carbon atoms of the aliphatic chains, which
could be described by a bell-shaped curve with a maximum at
C12. This is a common structure−activity trend that is found in
a number of series of homologous compounds in medicinal
chemistry and can be explained in terms of docking within the
binding pocket of the pharmacological target (as it exists an
optimal number of carbon atoms that can be accommodated
into the pocket) and also in terms of variation of solubility and
bioavailability (when the chain length is too long the solubility
decreases and also the biological activity). Thus, the diﬀerence
of TLR4 functional activity of FP monosaccharides related to
FA chain length can be explained in terms of their interaction
with MD-2(/TLR4) and/or by their aggregation properties in a
solution.
The docking and MD simulation studies have shown that
FP10, FP7, and FP12 would accomplish optimal binding
properties, while FP116 could be bordering the limits of the
maximum length compatible with a proper MD-2 binding.
Although MD-2 pocket is able to host up to ﬁve FA chains, the
highly long and ﬂexible C16 acyl chains present in FP116 seem
to point to less eﬃcient ability to interact with TLR4/MD-2 in
Figure 11. FP12 negatively regulates p65 NF-κB phosphorylation and production of IL-6 and IL-1β in THP-1 cells. THP-1 cells were pretreated
with compound FP12 (0−10 μM) for 1 h prior to LPS exposure. Cells were then left to incubate 1 and 16 h further in presence or absence of LPS
(100 ng/mL). p65 NF-κB phosphorylation was determined in cell lysates using Western blot analysis, and cytokine production was measured by
ELISA after 16 h of LPS exposure, respectively. Results are displayed as mean concentration ± SD of three independent experiments. Signiﬁcant
results are indicated as *P > 0.05, **P > 0.01, ***P > 0.001 for LPS vs control and LPS vs FP12 treated samples (ANOVA).
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an antagonistic binding mode, given that the required exposed
conformation of Phe126 side chain could be jeopardized.
Additionally, calculated logP values for the FP variants point
to a very high lipophilicity for FP116, maybe aﬀecting the
aggregation properties in solution.
Taken together, these data strongly suggest that the
mechanism of TLR4 antagonism of that class of compounds
is mainly based on the competition with LPS (or other ligands,
as bis-ANS) in the binding to the MD-2/TLR4 complex.
Interestingly, an identical order of activity on TLR4 has been
found in a series of monosaccharide TLR4 agonists, the Gifu
Lipid As (GLA), and the following order of potency in inducing
the production of TNF-α in murine cells was detected: C12 >
C14 > C10≫ C16.22 Also in the case of GLA compounds, with
three FA chains and one phosphate in C-4 position, the C12
and C14 variants were the most active ones, C10 was less
active, and C16 was inactive. Similarly to FP compounds, GLA
is more active on murine than on human cells.22 However, the
authors did not provide any evidence or explanation about the
link between TLR4 activity of monosaccharide and FA chain
length.
Regarding the aggregation properties, some important
diﬀerences among FP compounds were detected by FT-IR
analysis in solution. These measurements showed marked
variations in acyl chain ﬂuidity of aggregated FP compounds
depending on the chemical structure. The phase transition
temperature Tc exhibits a clear inverse correlation with the
length of the acyl chains with Tc C16≫ Tc C14 > Tc C12 > Tc
C10. Of note, this behavior results in marked diﬀerences at the
biologically relevant temperature of 37 °C, where FP10, FP12,
and FP7 are in a ﬂuid membrane phase, whereas FP116 is still
in a rigid membrane phase and requires much higher
temperatures for acyl chain melting to occur. The occurrence
of a very broad phase transition at temperatures above 37 °C
and occurrence of a second phase transition at higher
temperature as observed for FP116 were also found for inactive
glucosamine monosaccharide GLA compounds.40 Diﬀerences
in phase behavior have also been shown for the TLR4 ligands
lipid A and LPS. The antagonistic tetraacylated synthetic
compound 406 is highly ﬂuid at 37 °C, whereas the biologically
active hexaacylated compound 506 and LPS Re have phase
transition temperatures above 37 °C.41 The ﬂuidity state of the
acyl chains in aggregated glycolipids is thus not an exclusive
determinant of inﬂammatory or antagonistic activity of
chemically diﬀerent compounds. It is rather a modifying
parameter of biological activity by aﬀecting aggregate properties
such as hydrophobic thickness, packing density, and aggregate
stability. NMR and SAXS analysis revealed striking diﬀerences
in aggregate formation of FP compounds, which are likely to
explain diﬀerences in their biological activity. Concentration-
dependent NMR analysis of the two most antagonistic
compounds FP12 and FP7 revealed aggregation of FP7
(C14) at much lower concentrations than FP12 (C12),
reﬂecting further diﬀerences in the biophysical state and
bioavailability of these compounds. Aggregate structures
resolved by SAXS analysis provided evidence for lamellar
bilayer structures for FP10 and FP12, which are associated with
antagonistic activity; for FP7, a tendency for nonlamellar
structures was determined. Considering the crucial role of lipid
supramolecular aggregate structure for the presentation to LPS
receptor molecules, the diﬀerent aggregate structures observed
by SAXS might explain the slightly lower antagonistic activity of
FP7 compared to FP12 in some biological systems.
The present study provides structural and functional
biological data demonstrating the ability of novel FP variants
to negatively regulate TLR4 signaling in diﬀerent cell model
systems. Having shown the strong potential of FP12 to
modulate second messenger activation and various end points
of TLR4 signaling pathways including its lack of toxicity, this
study supports the idea of further drug development of FP12 as
a lead compound in preclinical and clinical studies for
pharmacological intervention of inﬂammatory-based diseases.
■ EXPERIMENTAL SECTION
Computational Studies. Structure Construction and Reﬁne-
ment. The 3D structures of ligands FP10, FP12, FP7, and FP116 were
built with PyMOL42 using 6YA monosaccharide found in the
GLYCAM database (http://glycam.org) as a template. The 3D
coordinates of human TLR4/MD-2 model in the antagonist
conformation is reported elsewhere.43
Parameters Derivation. The parameters needed for MD
simulations were obtained using the standard Antechamber procedure
in Amber14.44 Brieﬂy, ligand structures, already reﬁned at the AM1
level of theory, were optimized, and their atomic partial charges were
calculated with Gaussian09/e145 at the Hartree−Fock level (HF/6-
31G* Pop = MK iop(6/33 = 2), iop(6/42 = 6)), then the partial
charges were derived and formatted for AmberTools15 and Amber14
with Antechamber, assigning the general AMBER force ﬁeld (GAFF)
atom types. Later, the atom types of the atom constituting the
saccharide ring were changed to the GLYCAM force ﬁeld atom
types.46 The GAFF parameters for the phosphate group were modiﬁed
as shown in the Supporting Information.
Docking Calculations of Ligands FP10, FP12, FP7, and FP116.
The Gasteiger charges were computed within the AutoDockTools
1.5.6 program,47 and the nonpolar hydrogens were merged for all the
ligands, the human TLR4/MD-2 antagonist model, and human CD14
(PDB-ID 4GLP). AutoDock VINA 1.1.2 was used for the docking of
the ligands, and AutoDock 4.2 was used to redock the best-predicted
binding poses. In AutoDock 4.2, the Lamarckian evolutionary
algorithm was chosen, and all parameters were kept default except
for the number of genetic algorithm runs, which was set to 200 to
enhance the sampling. AutoDockTools 1.5.6 was used to assign the
Gasteiger−Marsili empirical atomic partial charges to the atoms of
both the ligands and the receptors. The structure of the receptors was
always kept rigid, whereas the structure of the ligand was set partially
ﬂexible by providing freedom to some appropriately selected dihedral
angles. Regarding the docking boxes, spacing was set to the default
value of 1 Å for VINA, and 0.375 Å for AutoDock. For human CD14
structure, the size of the box was set to 33.00 Å in the x-axis, 33.75 Å
in the y-axis, and 33.75 Å in the z-axis, and the center of the box was
located equidistant to the center of mass of residues Phe69, Tyr82, and
Leu89. For the human TLR4/MD-2 system, the size of the box was set
to 33.00 Å in the x-axis, 40.50 Å in the y-axis, and 35.25 Å in the z-axis,
and the center of the box was located equidistant to the center of mass
of residues Arg90 (MD-2), Lys122 (MD-2), and Arg264 (TLR4).
Molecular Dynamics (MD) Simulations. Selected docked com-
plexes were submitted to MD simulations for 50 ns in Amber14 suite.
All the complexes followed the same procedure. First, the system is
submitted to 1000 steps of the steepest descent algorithm followed by
7000 steps of the conjugate gradient algorithm. A 100 kcal·mol−1·A−2
harmonic potential constraint is applied on both the proteins and the
ligand. In the subsequent steps, the harmonic potential is progressively
lowered (respectively to 10, 5, and 2.5 kcal·mol−1·A−2) for 600 steps of
the conjugate gradient algorithm each time, and then the whole system
is minimized uniformly. Next, the system is heated from 0 to 100 K
using the Langevin thermostat in the canonical ensemble (NVT) while
applying a 20 kcal·mol−1·A−2 harmonic potential restraint on the
proteins and the ligand. Finally, the system is heated up from 100 to
300 K in the isothermal−isobaric ensemble (NPT) under the same
restraint condition as the previous step, followed by a simulation for
100 ps with no harmonic restraint applied. At this point, the system is
ready for the production run, which is performed using the Langevin
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thermostat under NPT ensemble, at a 2 fs time step. All production
runs were performed for 50 ns.
LogP Calculations. LogP values of FP10, FP12, FP7, and FP116
were calculated within the Maestro package.48
Chemistry. General. The reactions were carried out under a
nitrogen atmosphere. TLC was performed using prepared plates of
silica gel (Merck 60 F254 on aluminum) and revealed using UV light
or staining reagents (H2SO4 (5% in EtOH), ninhydrin (5% in EtOH),
basic solution of KMnO4 (0.75% in H2O), molibdate solution
(molybdatophosphorus acid and Ce(IV) sulfate in 4% sulfuric acid).
1H NMR (400 MHz) and 13C NMR spectra (100 MHz) were
recorded on a Varian spectrometer using partially deuterated solvents
as internal standards. Purity of ﬁnal compounds was ≥95% as assessed
by quantitative NMR analysis. Reaction conditions and compound
characterization are described in the Supporting Information.
HEK-Blue hTLR4 Cells Assay. HEK-Blue hTLR4 cells (InvivoGen)
were cultured according to manufacturer’s instructions. Brieﬂy, cells
were cultured in DMEM high glucose medium supplemented with
10% fetal bovine serum (FBS), 2 mM glutamine, antibiotics, and 1×
HEK-Blue Selection (InvivoGen). Cells were detached using a cell
scraper, counted, and seeded in a 96-well multiwell plate at a density of
4 × 104 cells per well. After overnight incubation (37 °C, 5% CO2,
95% humidity), supernatants were replaced with new medium
supplemented by the compound to be tested dissolved in water or
DMSO−H2O (1:1). After 30 min of preincubation, cells were
stimulated with 100 ng/mL LPS from E. coli O55:B5 (Sigma-Aldrich)
and incubated overnight. The SEAP-containing supernatants were
collected and incubated with para-nitrophenylphosphate (pNPP) for
2−4 h in the dark at room temperature. The well’s optical density was
determined using a microplate reader set to 405 nm. The results were
normalized with positive control (LPS alone) and expressed as the
mean of percentage ± SEM of at least three independent experiments.
RAW-Blue Cells. Raw-Blue cells (InvivoGen) were cultured
according to the manufacturer’s instructions. Brieﬂy, cells were
cultured in DMEM high glucose medium supplemented with 10%
fetal bovine serum (FBS), 2 mM glutamine, 100 μg/mL Normocin
(InvivoGen), and 200 μg/mL Zeocin (InvivoGen). Cells were
detached using a cell scraper, and the cell concentration was estimated
by using Trypan Blue (Sigma-Aldrich). The cells were diluted in
DMEM high glucose medium supplemented as described before and
seeded in 96-well multiwell plate at a density of 6 × 104 cells per well
in 200 μL. After overnight incubation (37 °C, 5% CO2, 95%
humidity), supernatant was removed, and cell monolayers were
washed with warm PBS, treated with increasing concentrations of
compounds dissolved in DMSO−H2O (1:1), and diluted in DMEM.
After 30 min, cells were stimulated with 10 ng/mL of LPS from E. coli
O55:B5 (Sigma-Aldrich) for 16 h. The supernatants were collected
and incubated with pNPP for 2−4 h in the dark at room temperature.
The optical density of wells was determined using a microplate reader
set to 405 nm. The results were normalized with positive control (LPS
alone) and expressed as the mean of percentage ± SEM of at least
three independent experiments.
THP-1 Cells. THP-1 cells were cultured in RPMI (+10% heat
inactivated fetal bovine serum (HiFPS), +1% glutamine, +1%
penicillin/streptamycin). Cells were split three times weekly and
maintained at a density of 0.3 × 106 cells/mL. For experimental
procedures, THP-1 was used at a density 0.5 × 106 cells/mL, 100 L/
well (96 wells), and 3 mL/well (six wells) plates, respectively. All cells
were pretreated with FP7 variants (0−10 M) for 1 h, then exposed to
LPS (100 ng/mL) for 1 or 16 h.
MTT Cell Viability Assay. HEK-Blue hTLR4 cells were grown in
DMEM supplemented with 10% FBS, 2 mM glutamine, and
antibiotics. Cells were seeded in 100 μL of DMEM without Phenol
Red at a density of 4 × 104 cells per well and incubated overnight (37
°C, 5% CO2, 95% humidity). Cells were treated with the higher dose
of compound used in the previous experiments and incubated
overnight. MTT solution (5 mg/mL in PBS) was added to each
well, and after 3 h incubation, 0.1 N HCl in 2-propanol solution was
used to dissolve formazan crystals. Formazan concentration was
determined by measuring the absorbance at 570 nm. The results were
normalized with untreated control (PBS) and expressed as the mean of
percentage ± SEM of three independent experiments.
Preparation of Recombinant hMD-2 in Escherichia coli and
Puriﬁcation. hMD-2 was produced in E. coli as described previously,49
analyzed by SDS−PAGE, and its biological activity tested on 293/
hTLR4a cells.
Preparation of Recombinant hMD-2 in Pichia pastoris and
Puriﬁcation. hMD-2 was produced in Pichia pastoris, analyzed by
SDS−PAGE, and its biological activity tested on 293/hTLR4a cells.
The coding sequence of mature hMD-2 was ampliﬁed by PCR
(primers F-hMD2-Q19 CAGAAGCAGTATTGGGTCTGC and R-
Spe-hMD2 TTTACTAGTATTTGAATTAGGTTGGTGTAGG)
from a plasmid template and ligated into the SnaBI/SpeI opened
pPpT4AlphaS-His expression vector (under the control of AOX1
promoter), in frame with the N-terminal S. cerevisiae α-MF prepro
leader sequence and the C-terminal 6xHis tag. The resulting
recombinant plasmid pPpT4AlphaS-His was transformed into E. coli
DH5α competent cells, and the positive recombinant plasmid, which
was conﬁrmed by DNA sequencing, was linearized and transformed
into Pichia pastoris GS115 by electroporation. MD-2 expressing
transformant was selected and cultured in a 250 mL shake ﬂask
containing 10 mL of YPD liquid media at 28 °C for 24 h. Two liter
ﬂasks containing 250 mL of BMGY (1% glycerol) medium at 28 °C
were inoculated with 1 mL of overnight inoculum. After being cultured
for 24 h, cells were aseptically collected by centrifugation at room
temperature for 10 min at 5000 rpm. BMGY medium was replaced
with 250 mL of methanol-complex medium BMMY (1% methanol) to
induce protein expression at 28 °C (250 rpm), adding 1% of methanol
every 12 h. After 2 days of fermentation in BMMY, cells were removed
by centrifugation 10 min at 5000 rpm. Supernatant was supplemented
with 2 mM MgCl2 (Sigma) and d100 mg/L of reduced glutathione
(Sigma), and pH was adjusted to 7.5 with NaOH (Sigma). Precipitate
was removed by centrifugation for 20 min at 1900g, followed by
ﬁltration using Stericup-GP 0.22 μm (Sigma). A 0.5 M solution of Tris
HCl pH 7.5 and 1.5 M NaCl (Sigma) was added to the medium to a
ﬁnal concentration of 50 mM Tris HCl and 150 mM NaCl. High
density nickel resin (ABT) was added to the medium (30 mL every
liter of medium) and incubated in batch at room temperature for 4 h.
High density nickel resin was washed several times with 50 mM Tris
HCl pH 7.5 and 150 mM NaCl solution. hMD-2 was eluted with 0.5
M imidazole (Sigma) in 2 mL fractions, which were analyzed for
protein concentration and by SDS-PAGE. Pooled fractions containing
hMD-2 were extensively dialyzed against 50 mM Tris, 150 mM NaCl,
and 0.5% Tween 20, pH 7.5 at 4 °C, and puriﬁed hMD-2 biological
activity was tested on 293/hTLR4a cells.
Preparation of Recombinant hMD-2 in Mammalian Cells and
Puriﬁcation. hMD-2 was produced in HEK293T cells, analyzed by
SDS−PAGE, and its biological activity tested on 293/hTLR4a cells.
HEK293T cells were grown in high-glucose DMEM medium
supplemented with 10% fetal calf serum, 106 units per L of penicillin
G and 1 g L−L of streptomycin in a 5% CO2 atmosphere at 37 °C.
Mammalian expression constructs for secreted proteins carrying a N-
terminal FLAG-tag were generated in the pEF vector (Thermo Fisher
Scientiﬁc). pEF-Flag-DEVD-hMD2-myc/His plasmid was transiently
transfected to HEK293T cells, and the cells were harvested 48 h after
transfection and resuspended in lysis buﬀer containing 50 mM Tris,
150 mM NaCl, 1 mM EDTA, and 1% TRITON X-100. The cell
suspension was homogenized by Dounce homogenizer and clariﬁed by
centrifugation at 10,000g for 20 min. ANTI-FLAG M2 aﬃnity gel
beads (SIGMA) was added to the lysate, and then it was left shaking at
4 °C overnight. Solution was spin down at 1000 rpm for 2 min and
eluted with TBS Flag peptide (100 μL/mL). Recombinant protein
hMD-2 was conﬁrmed by Western blot analysis using an HRP-coupled
antibody directed against the FLAG-tag at 1:5000 dilution ratio
(Invitrogen).
SDS-PAGE and Western Blot. Puriﬁed recombinant hMD-2 was
analyzed on 15% SDS-PAGE under reducing conditions followed by
Coomassie Brilliant Blue staining. For Western blot analysis, proteins
were separated by SDS-PAGE under reducing conditions and then
electrophoretically transferred onto polyvinylidene diﬂuoride mem-
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branes (Amersham Biosciences). After protein transfer, the mem-
branes were treated with blocking buﬀer followed by incubation with
anti-His-HRP antibodies (Sigma). Then, the bands were visualized by
3,3′-diaminobenzidine (Sigma) as a peroxidase substrate.
Protein Concentration Determination. The total protein concen-
tration was determined using ultraviolet absorption at 280 nm. The
theoretical extinction coeﬃcient (19.285) was obtained using the
protein sequence of hMD-2.
hMD-2 Activity Test Using 293/hTLR4a Cells. For measuring the
activity of recombinant expressed hMD-2, HEK 293 cells stably
transfected with the human TLR4a gene (293/hTLR4a (Invivogen))
were used. Various dilutions of hMD-2 (stock concentration was 10
μM) were incubated with 100 ng/mL of LPS (Sigma) prior to
stimulation of 293/hTLR4a cells. Supernatants were analyzed for IL-8
secretion by ELISA assay.
Determination of IL-8 Secretion by Sandwich Enzyme-Linked
Immunosorbent Assay. IL-8 concentrations were assayed using the
IL-8 Cytosets (Invitrogen) antibody pair kit containing matched,
pretitrated, and fully optimized capture and detection antibodies,
recombinant IL-8 standard, and streptavidin-horseradish peroxidase
(Sigma). The assay was conducted according to the manufacturer’s
speciﬁcations.
Antibody-Sandwich ELISA for the Detection of Binding of
Compounds to hMD-2. The method of antibody-sandwich ELISA
for the detection of the binding of compounds to MD-2 was modiﬁed
from a previous study.36 A microtiter plate was coated overnight at 4
°C with 100 μL/well of 5 μg/mL of chicken polyclonal anti-hMD-2
antibodies, diluted in 50 mM Na2CO3 buﬀer, pH 9.6, and blocked with
1% BSA in PBS. After washing, 1 μM hMD-2 with tested compounds
was added and incubated for 2 h. Mouse anti-hMD-2 mAb (0.1 μg/
mL, 9B4) and goat antimouse IgG conjugated with HRP (0.1 μg/mL)
in PBS were added, followed by detection at 420 nm after the addition
of 100 μL of ABTS (Sigma). Chicken anti-hMD-2 polyclonal
antibodies were prepared against recombinant hMD-2 by GenTel
(Madison, WI, USA), monoclonal mouse anti-hMD-2 9B4 antibodies
were from eBioscience (San Diego, CA, USA), and secondary goat
antimouse IgG conjugated with horseradish peroxidase was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
Fluorescence Spectroscopy Assay. Fluorescence was measured on
PerkinElmer ﬂuorimeter LS 55 (PerkinElmer, UK) as previously
described.38 All measurements were done at 20 °C in a 5 × 5 mm
quartz glass cuvette (Hellma Suprasil, Müllheim, Germany). hMD-2
protein (200 nM) and 1,1′-Bis(anilino)-4,4′-bis (naphthalene)-8,8′
disulfonate (bis-ANS, 200 nM) were mixed and incubated until
reaching stable relative ﬂuorescence units (RFUs) emitted at 420−550
nm under excitation at 385 nm. Compounds, at diﬀerent
concentrations, were then added, followed by relative ﬂuorescence
unit (RFU) measurement at 420−550 nm.
LPS Displacement Assay. The ability of the compounds to displace
LPS from hMD-2 hydrophobic pocket was determined by ELISA. A
microtiter plate was coated overnight at 4 °C with 100 μL/well of 5
μg/mL chicken polyclonal anti-hMD-2 antibodies, diluted in 50 mM
Na2CO3 buﬀer, pH 9.6, and blocked with 1% BSA in PBS. After
washing, 1 μM hMD-2 with biotin-labeled LPS was added and
incubated for 2 h. After washing, the compounds were added at
diﬀerent concentrations and incubated for 1.5 h. After washing, 0.5
μg/mL HRP-conjugated streptavidin (Sigma) in PBS was added,
followed by detection at 420 nm after the addition of 100 μL of ABTS
(Sigma). Chicken anti-hMD-2 polyclonal antibodies were prepared
against recombinant hMD-2 by GenTel (Madison, WI, USA).
Surface Plasmon Resonance (SPR) Analysis. The binding aﬃnity
of the compounds to recombinant hMD-2 was determined using a
Biacore X100 with an NTA sensor chip (Biacore, GE Healthcare,
Uppsala, Sweden). Brieﬂy, 0.5 μM hMD-2 (in 50 mM Tris, 150 mM
NaCl, 0.5% Tween 20, pH 7.5) was immobilized onto the sensor chip
previously activated with 1 min pulse of 10 mM NiSO4. The ﬁrst ﬂow
cell was used as a reference surface to control nonspeciﬁc binding.
Both ﬂow cells were injected with the analyte (in PBS, 5% DMSO, 5%
EtOH, pH 7.5) at a ﬂow rate of 10 μL/min at 25 °C in increasing
concentrations. The data were analyzed with Biacore Evaluation
software. KD values were calculated by global ﬁtting of the equilibrium
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